Treatment of inflammatory @entity1103 with humanized anti- XXXX antibody therapy.

@entity1 @entity2940 @entity1596 @entity1103 @entity1453 @entity1020
PURPOSE: To evaluate the safety and efficacy of treating @entity1103 , secondary to noninfectious @entity1596 , with a humanized anti- @entity1453 antibody. METHODS: Six @entity1 received weekly subcutaneous treatments for 16 weeks according to this open-label, prospective, noncomparative phase I/II trial. Best corrected visual acuity (BCVA) and @entity1020 ( @entity1020 ) were compared to baseline. Adverse events were recorded and assessed. Blood was sampled to assess the levels of @entity2940 (bright) regulatory NK cells before initiation and after termination of the study. RESULTS: No serious adverse events were reported by the @entity1 . @entity1 ' ages ranged from 22 to 82 years. Mean BCVA improvements were 6.7    6.9 ETDRS letters in the worse eye and 1.7    5.2 letters in the better eye. Mean @entity1020 reductions were 128    105  m in the worse eye and 57    68  m in the better eye. Anti- @entity1453 antibody treatments resulted in an increase in the @entity2940 (bright) regulatory NK cell population in the peripheral blood of the patients. CONCLUSIONS: Anti- @entity1453 treatment improved visual function, reduced macular thickness, and increased the level of @entity2940 (bright) regulatory NK cells in @entity1 with uveitic @entity1103 refractory to other immunosuppressive medications. Targeting @entity1453 may be beneficial in treating other causes of @entity1103 .
